immunogenicity of era g 333 strain in foxes and raccoon dogs d. bankovskiy(1, 2), g. safonov(1) and...

IMMUNOGENICITY OF ERA G 333 STRAIN IMMUNOGENICITY OF ERA G 333 STRAIN IN FOXES AND RACCOON DOGSIN FOXES AND RACCOON DOGS

D. Bankovskiy(1, 2), G. Safonov(1) and Y. Kurilchuk(1)D. Bankovskiy(1, 2), G. Safonov(1) and Y. Kurilchuk(1)

(1) Pokrov Plant of Biologics, Volginskiy, Russia.(1) Pokrov Plant of Biologics, Volginskiy, Russia.(2) All-Russian Research Institute of Veterinary Virology (2) All-Russian Research Institute of Veterinary Virology and Microbiology, Pokrov, Russia.and Microbiology, Pokrov, Russia.

Oral vaccinationOral vaccination

Two oral vaccines have been used for wild Two oral vaccines have been used for wild life rabies vaccination in Russialife rabies vaccination in Russia

Not enough vaccine quantity have been used Not enough vaccine quantity have been used for ORV campaigns for ORV campaigns

There was concern about safety and efficacy There was concern about safety and efficacy of vaccine rabies strains of vaccine rabies strains

Russia still needs a safe and efficient vaccine Russia still needs a safe and efficient vaccine strainstrain

ERA G 333ERA G 333

Created by reversed geneticsCreated by reversed genetics Have been received from collaborators Have been received from collaborators

at CDCat CDC As part of BTEP programAs part of BTEP program Avirulent for 11 species of target and Avirulent for 11 species of target and

non target animalsnon target animals

The immunogenicity experiment design. Part I: foxesThe immunogenicity experiment design. Part I: foxes

SpeciesSpecies ## VNA titers, IU/mlVNA titers, IU/ml Day Day of of

deathdeath

CommentsComments Before Before challengechallenge

Day 30 Day 30 after after challengechallenge

Day 60 after Day 60 after challengechallenge

foxfox 11 4.464.46 7.747.74 5.875.87 --

foxfox 22 <0.04<0.04 2.562.56 1.121.12 --

foxfox 33 2.562.56 0.870.87 0.650.65 --

foxfox 44 <0.04<0.04 2.562.56 0.860.86 --

foxfox 55 1.121.12 1.141.14 1.121.12 --

foxfox 66 5.875.87 1.121.12 1.501.50 --

foxfox 77 1.121.12 2.512.51 1.991.99 --

foxfox 88 <0.04<0.04 0.650.65 0.870.87 --

foxfox 99 0.130.13 0.500.50 0.290.29 --

foxfox 1010 0.850.85 0.870.87 1.141.14 --

foxfox 1111 <0.04<0.04 -- -- 2020thth

foxfox 1212 <0.04<0.04 -- -- 1515thth unvaccinated controlunvaccinated control

foxfox 1313 <0.04<0.04 -- -- 1717thth unvaccinated controlunvaccinated control

foxfox 1414 <0.04<0.04 -- -- 2121stst unvaccinated controlunvaccinated control

The immunogenicity experiment design. Part II: raccoon dogsThe immunogenicity experiment design. Part II: raccoon dogs

SpeciesSpecies ## VNA titers, IU/mlVNA titers, IU/ml Day Day of of

deathdeath

CommentsComments Before Before challengechallenge



Raccoon dogRaccoon dog 11 13.4513.45 13.4613.46 10.4410.44 --



Raccoon dogRaccoon dog 44 <0.04<0.04 -- -- 1212thth unvaccinated unvaccinated controlcontrol

Raccoon dogRaccoon dog 55 <0.04<0.04 -- -- 1414thth


Raccoon dogRaccoon dog 77 <0.04<0.04 0.500.50 0.860.86 --

Raccoon dogRaccoon dog 88 <0.04<0.04 -- -- 2121stst


Raccoon dogRaccoon dog 1010 <0.04<0.04 -- -- 2222ndnd unvaccinated unvaccinated controlcontrol

Raccoon dogRaccoon dog 1111 <0.04<0.04 -- -- 1717thth unvaccinated unvaccinated controlcontrol

63%63% of foxes and of foxes and 33%33% of raccoon dogs showed of raccoon dogs showed seroconversion by day 60 after vaccination.seroconversion by day 60 after vaccination.

After challenge with virulent rabies virus strain After challenge with virulent rabies virus strain 90%90% of foxes and of foxes and 50%50% of raccoon dogs have of raccoon dogs have survived.survived.

RESULTSRESULTS

CONCLUSIONSCONCLUSIONS

The appropriate immunogenicity of ERA G 333 for The appropriate immunogenicity of ERA G 333 for foxes and raccoon dogs has been shown in this foxes and raccoon dogs has been shown in this experiment.experiment.

This strain is the strong candidate for new oral This strain is the strong candidate for new oral rabies vaccine.rabies vaccine.

The decision about future use of ERA G 333 strain The decision about future use of ERA G 333 strain can be made after the determination of immunity can be made after the determination of immunity duration and minimal efficient doze of the vaccine duration and minimal efficient doze of the vaccine virus.virus.

ACKNOWLEDGEMENTSACKNOWLEDGEMENTS

Pokrov Plant of BiologicsPokrov Plant of Biologics

Staff of the Rabies Program of CDCStaff of the Rabies Program of CDC

BTEPBTEP

immunogenicity of era g 333 strain in foxes and raccoon dogs d. bankovskiy(1, 2), g. safonov(1) and...

Documents